Company news
Veracyte, Inc. (NASDAQ:VCYT) news
Every Veracyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 4
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
April 28, 2022
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
April 26, 2022
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
April 19, 2022
Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
March 1, 2022
Veracyte Appoints Annie McGuire as General Counsel
February 28, 2022
Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
February 28, 2022
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
February 22, 2022
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
February 15, 2022
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
February 14, 2022
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 8, 2022
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
January 31, 2022
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
January 24, 2022
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
January 6, 2022
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
December 14, 2021
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
November 24, 2021
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
November 13, 2021
Veracyte Announces Third Quarter 2021 Financial Results
November 9, 2021
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
November 5, 2021
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
November 3, 2021
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
November 2, 2021
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
October 26, 2021
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
October 25, 2021
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
October 14, 2021
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
October 13, 2021
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
October 12, 2021
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
October 11, 2021
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
October 11, 2021
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
October 6, 2021
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
September 14, 2021
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
September 1, 2021
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
August 23, 2021
Veracyte Completes Acquisition of HalioDx
August 3, 2021
Veracyte Announces Second Quarter 2021 Financial Results
July 29, 2021
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
July 27, 2021
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
July 12, 2021
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
July 8, 2021
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
July 8, 2021
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
July 1, 2021
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
June 14, 2021
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
June 4, 2021
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
June 2, 2021
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
June 1, 2021
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
May 26, 2021
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
May 25, 2021
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
May 19, 2021
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
May 14, 2021
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
May 14, 2021
Veracyte Announces First Quarter 2021 Financial Results
May 10, 2021
Veracyte, Inc. Announces CEO Succession Plan
May 10, 2021